Guidance for the discontinuation or switching of antidepressant therapies in adults

Journal of Pharmacy Practice

Volumn 26, Issue 4, 2013, Pages 389-396

  Ogle, Nikki R ^a   Akkerman, Shawn R ^b  

^a UNIVERSITY OF KANSAS HOSPITAL   (United States)

^b NEBRASKA MEDICAL CENTER   (United States)

Author keywords

antidepressant; discontinuation; taper; withdrawal; withdrawal syndrome

Indexed keywords

ANTIDEPRESSANT AGENT;

ARTICLE; DRUG APPROVAL; DRUG FORMULARY; DRUG PACKAGING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; HEALTH CARE PERSONNEL; HUMAN; PRACTICE GUIDELINE; SEARCH ENGINE; WITHDRAWAL SYNDROME; ADULT;

ADULT; ANTIDEPRESSIVE AGENTS; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 84881160640     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190012467210     Document Type: Article

References (37)

1. Baldwin DS, Cooper JA, Huusomn AK, et al. A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder. Int Clin Psychopharmacol. 2006 ; 21 (3). 159-169
2. Perahia DG, Quail D, Desaiah D, et al. Switching to duloxetine from selective serotonin reuptake inhibitor antidepressants: a multicenter trial comparing 2 switching techniques. J Clin Psychiatry. 2008 ; 69 ((1)). 95-105
3. Tint A, Haddad PM, Anderson IM. The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: a randomised study. J Psychopharmacol. 2008 ; 22 (3). 330-332
4. Maixner SM, Gregen JF. Extended antidepressant maintenance and discontinuation syndromes. Depress Anxiety. 1998 ; 8 (suppl 1). 43-53
5. New York, NY: Pfizer, Inc ; 2007:
6. Research Triangle Park, NC: GlaxoSmithKline ; 2010:
7. Indianapolis, IN: Eli Lily and Company ; 2011:
8. Philadelphia, PA: Wyeth Pharmaceuticals, Inc ; 2010:
9. Philadelphia, PA: Wyeth Pharmaceuticals Inc ; 2011:
10. Indianapolis, IN: Eli Lily and Company ; 2006:
11. St Louis, MO: Forest Pharmaceuticals, Inc ; 2011:
12. St Louis, MO: Forest Pharmaceuticals, Inc ; 2011:
13. Baudette, MN: ANI Pharmaceuticals, Inc ; 2011:
14. Research Triangle Park, NC: GlaxoSmithKline ; 2011:
15. New York, NY: Pfizer, Inc ; 2011:
16. New Brunswick, NJ: Bristol Myers Squibb ; 2005:
17. Princeton, NJ: Apothecon ; 2005:
18. St Louis, MO: Forest Pharmaceuticals, Inc ; 2011:
19. Hazelwood, MO: Mallinckrodt, Inc ; 2007:
20. Greenville, NC: GlaxoSmithKline ; 2011:
21. Whitehouse Station, NJ: Merck & Co, Inc ; 2010:
22. Basow DS, ed. Waltham, MA: ; 2012:
23. Clinical Pharmacology. Tampa, FL: Gold Standard, Inc; 2012. http://clinicalpharmacology.com. Accessed August 25, 2011.
24. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc ;
25. Hudson, OH: Lexi-Comp, Inc ; 2011:
26. General guidelines for switching antidepressant medication (following >7 days exposure). South Carolina Offering Prescribing Excellence (SCORxE) Newsletter FAQs. 2010. http://www.sccp.sc.edu/centers/SCORxE/protected/ downloads/FINAL%20SCORE%20PDF%2012110.pdf. Accessed August 25, 2011.
27. MIMS Online. MIMS United Kingdom. Switching antidepressants: quick-reference guide to switching depression medication. http://www.mims.co.uk/ Tables/882430/Switching-Antidepressants/. Accessed August 25, 2011.
28. Schatzberg AF, Haddad P, Kaplan EM, et al. Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition. J Clin Psychiatry. 1997 ; 58 ((suppl 7)). 5-10
29. Haddad P. Newer antidepressants and the discontinuation syndrome. J Clin Psychiatry. 1997 ; 58 (suppl 7). 17-21
30. Lejoyeux M, Adès J. Antidepressant discontinuation: a review of the literature. J Clin Psychiatry. 1997 ; 58 (suppl 7). 11-15
31. Hirsch M, Birnbaum RJ Basow DS, ed. Waltham, MA: ; 2012:
32. Phelps J. Tapering antidepressants: is 3 months slow enough?. Med Hypotheses. 2011 ; 77 (6). 1006-1008
33. Rosenbaum JF, Zajecka J. Clinical management of antidepressant discontinuation. J Clin Psychiatry. 1997 ; 58 ((suppl 7)). 37-40
34. Sir A, D' Souza RF, Uguz S, et al. Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms. J Clin Psychiatry. 2005 ; 66 (10). 1312-1320
35. Shelton RC. Steps following attainment of remission: discontinuation of antidepressant therapy. Prim Care Companion J Clin Psychiatry. 2001 ; 3 ((4)). 168-174
36. Khan A, Nina PT, Ramey T, et al
37. Cohen LJ, Sloan DM. Desvenlafaxine: frequently asked questions. Primary Psychiatry. 2009 ; 16 (12). 1-8